In this study, we compared the clinical efficacy and safety of various Yiqi Chinese medicine injections in chronic pulmonary heart disease (CPHD) through pairwise meta-analyses and indirect comparisons within a systematic review.
A001 Targeting ZIP12 to Modulate Intracellular Zinc and Vascular Dysfunction in Pulmonary Arterial Hypertension, A002 Role of The Protein Ttk in the Vascular Remodeling Processes in Pulmonary Artery Hyerpenstion and more.
Placental Abnormalities of Malperfusion, Inflammation, and Meconium are Associated With Persistent Pulmonary Hypertension of the Newborn, Pulmonary Hypertension-Targeted Therapies in Adult and Pediatric Patients Supported With Ventricular Assist Devices: A Systematic Review and more.
Ventilatory inefficiency, assessed by the VE/VCO2 slope during cardiopulmonary exercise testing (CPET), is a key physiological marker. However, differences in ventilatory efficiency between chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH), as well as their response to treatment, remain incompletely characterized.
Pulmonary hypertension (PH) is frequently accompanied by a decline in kidney function. In this retrospective cohort, worsening PH was associated with long-term eGFR decline only when accompanied by transition from acute kidney injury (AKI) to acute kidney disease (AKD), defined as persistent kidney dysfunction beyond 7 days after AKI onset, whereas early AKI reversal was not.
